QMSR Inspection Readiness: Preparing for FDA Under Compliance Program 7382.850 (Part 2)

On February 2, 2026, FDA retired the Quality System Inspection Technique (QSIT) and implemented a new inspection process described in Compliance Program 7382.850. This change represents more than updated procedures—it reflects a fundamental shift in how FDA assesses medical device quality management systems under the QMSR.

For manufacturers and CROs, understanding the new inspection approach and preparing your quality system for FDA review is essential for maintaining compliance and avoiding observations that could impact market access.

This is Part 2 of our QMSR series. If you haven't read Part 1, start there for foundational understanding of what changed on February 2, 2026.

Understanding the New Inspection Process

Compliance Program 7382.850 emphasizes process-based assessment aligned with ISO 13485:2016 structure, replacing QSIT's prescriptive checklist approach. FDA investigators now evaluate how your QMS functions as an integrated system rather than checking isolated procedures against regulatory subsections.

Key characteristics of the new approach:

Process-based evaluation: Investigators assess whether your processes actually control quality and drive continuous improvement, not just whether documentation exists.

Risk-based inspection planning: FDA determines inspection scope based on device risk classification, manufacturing complexity, compliance history, and other risk factors.

Emphasis on effectiveness: Expect questions about how you use quality data, how decisions are made, and whether improvements actually occur.

Integration assessment: FDA looks at connections between QMS elements—how complaint data feeds CAPA, how design changes trigger risk reassessment, how supplier performance impacts incoming acceptance.

The most significant operational change is expanded inspection authority. FDA can now review management review reports, internal audit reports, and supplier audit reports that were previously exempt under 21 CFR Part 820.180(c).

What FDA Will Review During Inspections

Understanding what FDA investigators will examine helps you prepare inspection-ready documentation.

Management Review Records

Management reviews demonstrate executive engagement with quality system effectiveness. FDA will look for:

• Review inputs including audit results, customer feedback, complaint trends, process performance, and CAPA effectiveness

• Review outputs documenting substantive decisions about QMS improvement, product improvement, and resource allocation

• Follow-up actions showing how decisions were implemented and verified

• Evidence of data-driven decision-making, not perfunctory documentation

If your management reviews consistently show "no issues" or lack substantive decisions, investigators will question whether the process is effective.

Internal Audit Records

Internal audits provide independent QMS assessment. FDA will examine:

• Audit planning showing systematic coverage of all QMS elements

• Auditor qualifications demonstrating training, competence, and independence

• Audit findings documenting nonconformances and improvement opportunities

• Corrective actions with root cause analysis and effectiveness verification

FDA looks for audit programs that actually identify issues and drive improvement. If the same problems appear repeatedly without effective correction, or if audits never identify significant findings, investigators will question audit rigor.

Supplier Management Records

Supplier controls are critical to device quality. FDA will review:

• Supplier evaluation criteria and initial qualification documentation

• Ongoing performance monitoring and periodic re-evaluation

• Supplier audit reports for critical suppliers

• Supplier change management processes

FDA expects risk-based supplier management, with more rigorous oversight for suppliers providing materials with patient contact or affecting critical device characteristics.

Design Controls and Production Records

Design history files, production controls, and CAPA records remain focal points. FDA will assess:

Design controls: Planning, inputs, outputs, verification, validation, transfer, and change control with clear traceability. For devices requiring biocompatibility evaluation, FDA looks for integration of biological risk assessment into design controls.

Production controls: Process validation, environmental controls, equipment qualification, and ongoing monitoring demonstrating consistent manufacturing.

CAPA effectiveness: Root cause analysis, corrective action implementation, and verification that actions actually eliminated problems or prevented recurrence.

Preparing Previously Exempt Records for FDA Review

The expanded inspection authority requires immediate attention to records that were previously exempt.

Making Records Inspection-Ready

Review existing records for completeness and evidence of systematic quality management. Ask whether records demonstrate:

• Data-driven decision-making based on objective evidence

• Substantive actions and follow-up, not just documentation compliance

• Executive or management engagement with quality issues

• Continuous improvement driven by quality data

Address gaps proactively by documenting corrective actions for deficiencies in historical records and implementing improvements to ensure future records meet FDA expectations.

Establish clear procedures defining frequency, required participants, input requirements, output documentation, and follow-up processes for management reviews, audits, and supplier evaluations.

Train responsible personnel on their roles and FDA expectations so these activities generate meaningful quality improvements, not just compliance documentation.

Common Pitfalls to Avoid

Superficial documentation: Records that check boxes without demonstrating real quality management or improvement.

Lack of follow-through: Decisions or actions documented but not implemented or verified for effectiveness.

Recurring issues: The same problems appearing repeatedly without effective resolution, indicating ineffective CAPA or management review.

Inconsistent practices: Documentation showing one approach while actual practice differs, revealing gaps between procedures and reality.

Inspection Response Strategies

How you respond during and after FDA inspections significantly impacts outcomes.

During the Inspection

Provide requested records promptly. Have quality system records organized and readily retrievable. Delays raise concerns about record control.

Answer questions directly. Provide clear, factual answers. If you don't know, say so and commit to following up rather than speculating.

Demonstrate process understanding. Show that you understand how your QMS works and how it ensures device quality. Investigators assess whether your system is truly implemented or just documented.

Take notes. Document what the investigator reviews, questions asked, and concerns raised. This helps you prepare responses and implement corrective actions.

Responding to Form FDA 483 Observations

If FDA issues observations, your response is critical:

Respond promptly within 15 business days unless you request an extension.

Address each observation specifically by restating it, acknowledging the issue, and explaining what you found, what you're doing to correct it, and how you'll prevent recurrence.

Provide root cause analysis for significant observations, demonstrating you're addressing systemic issues, not just the specific instance cited.

Include timelines and responsibilities clearly stating what actions will be taken, who is responsible, and when completion is expected.

Verify effectiveness by explaining how you'll confirm corrective actions work and issues don't recur.

Avoid over-promising. Commit only to actions you can actually complete in the stated timeframe. Failure to complete committed actions creates additional compliance concerns.

Post-Inspection Follow-Up

Implement corrective actions on schedule and document implementation thoroughly.

Verify effectiveness through follow-up monitoring to ensure corrections actually addressed the issues.

Update quality system by incorporating lessons learned into procedures, training, and improvements.

Prepare for potential re-inspection if significant observations were issued.

Proactive Inspection Preparation

The best inspection strategy is ongoing readiness, not last-minute preparation.

Conduct Internal Mock Inspections

Use a process-based approach aligned with Compliance Program 7382.850, not just QSIT-style checklists. Review previously exempt records as if FDA were examining them. Test record retrieval to ensure documents are readily available and organized logically. Assess process integration to identify gaps in information flow or decision-making.

Maintain Continuous Compliance

Treat every day as inspection day by maintaining quality system records at inspection-ready status continuously.

Address issues promptly through real-time investigation, correction, and effectiveness verification.

Keep training current so all personnel understand their quality responsibilities and current procedures.

Monitor quality metrics and use data to drive proactive improvements before issues become FDA observations.

Engage Expert Support When Needed

Consider external experts for pre-inspection assessments, particularly if you haven't been inspected under the QMSR yet. For complex issues like biocompatibility evaluation or toxicological risk assessment, engage qualified consultants who can ensure your approach meets FDA expectations. If you receive significant observations, expert support can help develop comprehensive, scientifically sound responses addressing root causes effectively.

Key Takeaways for Inspection Readiness

FDA inspections under Compliance Program 7382.850 emphasize process effectiveness, QMS integration, and systematic quality management. The expanded inspection authority means management reviews, internal audits, and supplier audits must now be maintained as inspection-ready records demonstrating data-driven decision-making and continuous improvement.

Successful inspection readiness requires:

• Ongoing compliance maintained continuously, not just before inspections

• Inspection-ready records for previously exempt documents (management reviews, audits)

• Process integration showing how QMS elements work together

• Effectiveness focus demonstrating that your QMS actually drives quality and improvement

• Proactive preparation through internal assessments and gap identification

By maintaining your quality system at inspection-ready status and ensuring previously exempt records meet FDA expectations, you position your organization for successful FDA interactions under the QMSR.

In Part 3 of this series, we'll explore how biocompatibility evaluation integrates with QMSR requirements, including ISO 10993-1:2025 risk-based biological evaluation within design controls and quality system processes.

Expert QMSR Inspection Readiness Support

Preparing for FDA inspections under Compliance Program 7382.850 requires understanding of both quality system requirements and inspection strategies. At JL Tox Consulting, we help medical device manufacturers and CROs prepare for FDA inspections, address observations, and maintain continuous QMSR compliance.

Our inspection readiness services include:

• Mock inspections using the process-based approach of Compliance Program 7382.850

• Gap assessments identifying compliance issues before FDA inspection

• Documentation review ensuring management reviews, audits, and supplier records meet FDA expectations

• Form FDA 483 response preparation with scientifically sound corrective action plans

• Biocompatibility and toxicology support for design control questions

Contact JL Tox Consulting to prepare for FDA inspection under the QMSR:

Email: info@JLTox.com

Phone: (877) 899-6568